Domača stranTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Prejšnji trg. dan.
4,80 $
Dnevni razpon
4,53 $ - 4,81 $
Letni razpon
4,24 $ - 14,80 $
Tržna kapitalizacija
4,27 mio. USD
Povprečni obseg
19,75 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 2,07 mio. | 68,76 % |
Čisti dohodek | −2,09 mio. | −31,97 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | — | — |
EBITDA | −2,07 mio. | −33,70 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 4,09 mio. | 3.797,14 % |
Skupna sredstva | 4,35 mio. | 435,71 % |
Skupne obveznosti | 356,00 tis. | −80,72 % |
Celoten lastniški kapital | 3,99 mio. | — |
Shares outstanding | 914,23 tis. | — |
Razmerje P/B | 1,10 | — |
Donosnost sredstev | −94,31 % | — |
Donosnost kapitala | −102,53 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −2,09 mio. | −31,97 % |
Denar iz dejavnosti | −2,07 mio. | −85,97 % |
Denar iz naložb | — | — |
Denar iz financiranja | — | — |
Neto sprememba denarnih sredstev | −2,07 mio. | −85,97 % |
Prost denarni tok | −1,27 mio. | −22,46 % |
Vizitka
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Datum ustanovitve
1991
Sedež organizacije
Spletno mesto
Zaposleni
4
